Mercia Pharma Inc., NY, has obtained a worldwide license from Nova Laboratories Limited, UK to a proprietary Trehalose glass protein stabilization technology for use in Mercia’s vaccines. This technology uniquely allows proteins to be stabilized in a spray-dried formulation while maintaining full activity over extended periods at room temperature or above. Peter Blackburn, President of Mercia, stated, “ We have a strong relationship with Nova. Mercia previously entered into a partnership with Nova that gives Mercia full manufacturing capabilities for our products without having to build infrastructure. Now we have entered a new phase of our relationship whereby Mercia has gained access to complementary technology that synergizes with our MERIT platform.” As part of the transaction, Nova acquired an equity stake in Mercia.